Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
European Radiology
Published in: European Radiology 9/2014

01-09-2014 | Breast

Tumour volume doubling time of molecular breast cancer subtypes assessed by serial breast ultrasound

Authors: Eun Bi Ryu, Jung Min Chang, Mirinae Seo, Sun Ah Kim, Ji He Lim, Woo Kyung Moon

Published in: European Radiology | Issue 9/2014

Login to get access

Abstract

Objectives

The aim of our study was to evaluate the tumour volume doubling time (TVDT) of molecular breast cancer subtypes by serial ultrasound (US).

Methods

Sixty-six patients (mean age, 50 years; range, 29–78 years) with invasive breast cancer underwent initial and follow-up breast US examinations (at least three months apart) with no intervention. TVDT was determined using the tumours’ greatest dimensions in two orthogonal planes. The results were compared with clinical, imaging, and tumour variables and molecular subtypes (oestrogen receptor [ER]-positive, human epidermal growth factor receptor 2 [HER2]-positive, and triple negative) using a multiple linear regression analysis.

Results

TVDT exhibited a wide range (46–825 days; median, 141 days) with an overall mean of 193 ± 141 days and mean values of 241 ± 166 days for ER-positive tumours (n = 37), 162 ± 60 days for HER2-positive tumours (n = 12), and 103 ± 43 days for triple-negative tumours (n = 17) (P < 0.0001). In a multivariate regression analysis, compared to other features, only the different molecular breast cancer subtypes showed significant difference in TVDT (P < 0.0001).

Conclusions

TVDT differed significantly among the three molecular breast cancer subtypes, with the triple-negative tumours showing the fastest growth.

Key Points

• Knowledge of tumour volume doubling time provides clues for improving screening.
• TVDT assessed by serial US differed significantly between breast cancer subtypes.
• Triple-negative tumours had 2.4-fold shorter TVDT compared to ER-positive tumours.
• Tumours classified as BI-RADS 3 had shorter TVDT than BI-RADS 4.
Literature
1.
Friberg S, Mattson S (1997) On the growth rates of human malignant tumors: implications for medical decision making. J Surg Oncol 65:284–297PubMedCrossRef
2.
Peer PG, van Dijck JA, Hendriks JH, Holland R, Verbeek AL (1993) Age-dependent growth rate of primary breast cancer. Cancer 71:3547–3551PubMedCrossRef
3.
von Fournier D, Weber E, Hoeffken W, Bauer M, Kubli F, Barth V (1980) Growth rate of 147 mammary carcinomas. Cancer 45:2198–2207CrossRef
4.
5.
6.
Madeleine MA, Tilanus-Linthorst MM, Obdeijn IM et al (2007) BRCA1 mutation and young age predict fast breast cancer growth in the Dutch, United Kingdom, and Canadian magnetic resonance imaging screening trials. Clin Cancer Res 13:7357–7362CrossRef
7.
Bosch AM, Kessels AG, Beets GL et al (2003) Preoperative estimation of the pathological breast tumour size by physical examination, mammography and ultrasound: a prospective study on 105 invasive tumours. Eur J Radiol 48:285–292PubMedCrossRef
8.
Moon HJ, Kim EK, Kwak JY, Yoon JH, Kim MJ (2011) Interval growth of probably benign breast lesions on follow-up ultrasound: how can these be managed? Eur Radiol 21:908–918PubMedCrossRef
9.
Sorlie T, Perou CM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98:10869–10874PubMedCentralPubMedCrossRef
10.
Carey LA, Perou CM, Livasy CA et al (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295:2492–2502PubMedCrossRef
11.
Lin NU, Vanderplas A, Hughes ME et al (2012) Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer 118:5463–5472PubMedCentralPubMedCrossRef
12.
de Ronde JJ, Hannemann J, Halfwerk H et al (2010) Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response. Breast Cancer Res Treat 119:119–126PubMedCrossRef
13.
Dawson SJ, Duffy SW, Blows FM et al (2009) Molecular characteristics of screen-detected vs symptomatic breast cancers and their impact on survival. Br J Cancer 101:1338–1344PubMedCentralPubMedCrossRef
14.
Dogan BE, Gonzalez-Angulo AM, Gilcrease M, Dryden MJ, Yang WT (2010) Multimodality imaging of triple receptor-negative tumors with mammography, ultrasound, and MRI. AJR Am J Roentgenol 194:1160–1166PubMedCrossRef
15.
Ko ES, Lee BH, Kim HA, Noh WC, Kim MS, Lee SA (2010) Triple-negative breast cancer: correlation between imaging and pathological findings. Eur Radiol 20:1111–1117PubMedCrossRef
16.
Boisserie-Lacroix M, Macgrogan G, Debled M et al (2013) Triple-negative breast cancers: associations between imaging and pathological findings for triple-negative tumors compared with hormone receptor-positive/human epidermal growth factor receptor-2-negative breast cancers. Oncologist 18:802–811PubMedCentralPubMedCrossRef
17.
Mendelson EB, Baum JK, Berg WA, Merritt CRB, Rubin E (2003) Breast Imaging Reporting and Data System, BI-RADS: Ultrasound, 1st edn. American College of Radiology, Reston
18.
Tilanus-Linthorst MM, Kriege M, Boetes C et al (2005) Hereditary breast cancer growth rates and its impact on screening policy. Eur J Cancer 41:1610–1617PubMedCrossRef
19.
Hammond ME, Hayes DF, Wolff AC, Mangu PB, Temin S (2010) American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Oncol Pract 6:195–197PubMedCentralPubMedCrossRef
20.
Wolff AC, Hammond ME, Schwartz JN et al (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118–145PubMedCrossRef
21.
Cheang MC, Chia SK, Voduc D et al (2009) Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101:736–750PubMedCentralPubMedCrossRef
22.
Perou CM, Sorlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature 406:747–752PubMedCrossRef
23.
Turkoz FP, Solak M, Petekkaya I et al (2013) Association between common risk factors and molecular subtypes in breast cancer patients. Breast 22:344–350PubMedCrossRef
24.
Eklund M, Esserman LJ (2013) Screening: biology dictates the fate of young women with breast cancer. Nat Rev Clin Oncol 10:673–675PubMedCrossRef
25.
de Melo Gagliato D, Gonzalez-Angulo AM, Lei X et al (2014) Clinical impact of delaying initiation of adjuvant chemotherapy in patients with breast cancer. J Clin Oncol(Jan 27)
26.
Park S, Koo JS, Kim MS et al (2012) Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry. Breast 21:50–57PubMedCrossRef
27.
Lee JA, Kim KI, Bae JW et al (2010) Triple negative breast cancer in Korea-distinct biology with different impact of prognostic factors on survival. Breast Cancer Res Treat 123:177–178PubMedCrossRef
28.
Norton L (1988) A Gompertzian model of human breast cancer growth. Cancer Res 48(24 Pt 1):7067–7071PubMed
29.
Demicheli R, Terenziani M, Valagussa P, Moliterni A, Zambetti M, Bonadonna G (1994) Local recurrences following mastectomy: support for the concept of tumor dormancy. J Natl Cancer Inst 86:45–48PubMedCrossRef
30.
Stavros AT (2003) Breast ultrasound. Lippincott Williams & Wilkins, Philadelphia, PA, pp 490–491
31.
Berg WA, Cosgrove DO, Doré CJ et al (2012) Shear-wave elastography improves the specificity of breast US: the BE1 multinational study of 939 masses. Radiology 262:435–449PubMedCrossRef
32.
Cho N, Jang M, Lyou CY, Park JS, Choi HY, Moon WK (2012) Distinguishing benign from malignant masses at breast US: combined US elastography and color doppler US–influence on radiologist accuracy. Radiology 262:80–90PubMedCrossRef
33.
Weedon-Fekjaer H, Lindqvist BH, Vatten LJ, Aalen OO, Tretli S (2008) Breast cancer tumor growth estimated through mammography screening data. Breast Cancer Res 10:R41PubMedCentralPubMedCrossRef
34.
Kelly KM, Dean J, Lee SJ, Comulada WS (2010) Breast cancer detection: radiologists’ performance using mammography with and without automated whole-breast ultrasound. Eur Radiol 20:2557–2564PubMedCentralPubMedCrossRef
35.
Kuroishi T, Tominaga S, Morimoto T et al (1990) Tumor growth rate and prognosis of breast cancer mainly detected by mass screening. Jpn J Cancer Res 81:454–462PubMedCrossRef
Metadata
Title
Tumour volume doubling time of molecular breast cancer subtypes assessed by serial breast ultrasound
Authors
Eun Bi Ryu
Jung Min Chang
Mirinae Seo
Sun Ah Kim
Ji He Lim
Woo Kyung Moon
Publication date
01-09-2014
Publisher
Springer Berlin Heidelberg
Published in
European Radiology / Issue 9/2014
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-014-3256-0

Other articles of this Issue 9/2014

European Radiology 9/2014 Go to the issue

Interventional

Diffusion-weighted magnetic resonance imaging using different b-value combinations for the evaluation of treatment results after volumetric MR-guided high-intensity focused ultrasound ablation of uterine fibroids

Chest

Prevalence and variables associated with solitary pulmonary nodules in a routine clinic-based population: a cross-sectional study

Computed Tomography

Quality control within the multicentre perfusion CT study of primary colorectal cancer (PROSPeCT): results of an iodine density phantom study

Hepatobiliary-Pancreas

Utility of contrast-enhanced ultrasound with perflubutane for diagnosing the macroscopic type of small nodular hepatocellular carcinomas

Gastrointestinal

MRI patterns of Nissen fundoplication: normal appearance and mechanisms of failure

Vascular-Interventional

Optimising the preoperative planning of deep inferior epigastric perforator flaps for breast reconstruction